A group of Australian researchers and an FDA-led team have independently identified a mechanism behind HLA allele-mediated autoimmune reactions to certain drugs. The findings could expand the use of HLA genotyping in drug design, clinical trials and patient care to improve therapeutic outcomes and safety.